Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Antibody titres in biological samples |
Immunogenicity of COVID-19 Vaccines: Seroconversion rates in vaccinated mothers, SARS-CoV-2 antibody titres and their persistence in mothers after vaccination in pregnancy, transfer of antibodies to breastmilk/chestmilk, transfer and persistence of SARS-CoV-2 antibodies to the neonate/infant over the study period. |
1-month post COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples |
Immunogenicity of COVID-19 Vaccines: Seroconversion rates in vaccinated mothers, SARS-CoV-2 antibody titres and their persistence in mothers after vaccination in pregnancy, transfer of antibodies to breastmilk/chestmilk, transfer and persistence of SARS-CoV-2 antibodies to the neonate/infant over the study period. |
3-month, and 6-month post COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples |
Immunogenicity of COVID-19 Vaccines: Seroconversion rates in vaccinated mothers, SARS-CoV-2 antibody titres and their persistence in mothers after vaccination in pregnancy, transfer of antibodies to breastmilk/chestmilk, transfer and persistence of SARS-CoV-2 antibodies to the neonate/infant over the study period. |
6-month post COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples |
Immunogenicity of COVID-19 Vaccines: Seroconversion rates in vaccinated mothers, SARS-CoV-2 antibody titres and their persistence in mothers after vaccination in pregnancy, transfer of antibodies to breastmilk/chestmilk, transfer and persistence of SARS-CoV-2 antibodies to the neonate/infant over the study period. |
At delivery |
|
Primary |
Antibody titres in biological samples of participants who received COVID-19 vaccine and who had natural COVID-19 disease. |
Comparing immune responses to COVID-19 vaccination in pregnant and non-pregnant women/individuals |
6-months post-COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples of participants who received COVID-19 vaccine and who had natural COVID-19 disease. |
Comparing immune responses to COVID-19 vaccination in pregnant and non-pregnant women/individuals |
3-month post-COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples of participants who received COVID-19 vaccine and who had natural COVID-19 disease. |
Comparing immune responses to COVID-19 vaccination in pregnant and non-pregnant women/individuals |
1-month post-COVID-19 vaccine |
|
Primary |
Antibody titres in biological samples of pregnant and non-pregnant populations |
Comparing infection-acquired and vaccine-acquired immunity against COVID-19 in mothers and newborns |
During delivery admission |
|
Secondary |
Maternal death |
Maternal death during delivery admission |
through study completion, an average of 9 months |
|
Secondary |
Maternal - Non-delivery hospitalization |
Any hospitalization not associated with the delivery of infant. |
through study completion, an average of 9 months) |
|
Secondary |
Any infection |
Maternal diagnosis of any infection during pregnancy |
through study completion, an average of 9 months |
|
Secondary |
Pre-term labour |
The onset of labour prior to 37 weeks gestation |
through study completion, an average of 9 months |
|
Secondary |
Hypertensive disorders of pregnancy |
The diagnosis of a hypertensive disorder of pregnancy |
through study completion, an average of 9 months |
|
Secondary |
Placental abruption |
The diagnosis of placental abruption during pregnancy |
through study completion, an average of 9 months |
|
Secondary |
Postpartum hemorrhage |
The diagnosis of postpartum hemorrhage |
Post-delivery, during the delivery admission |
|
Secondary |
Preterm birth |
Infant born prior to 37 weeks gestation |
through study completion, an average of 9 months |
|
Secondary |
Fetal loss or stillbirth |
Fetal loss or stillbirth throughout the pregnancy |
through study completion, an average of 9 months |
|
Secondary |
Small for gestational age |
<10th percentile for gestational age and sex- specific birth weight |
During the pregnancy, through study completion, an average of 9 months |
|
Secondary |
Term low birthweight |
<2500g |
At delivery |
|
Secondary |
Low 5 min Apgar Score |
Score <5 at 5 minutes |
At delivery |
|
Secondary |
Low cord blood pH |
cord blood pH<7.0 |
At delivery |
|
Secondary |
admission to neonatal ICU for >12 hours |
Infant admission to the neonatal ICU for >12 hours |
During delivery admission |
|
Secondary |
composite neonatal adverse outcome indicator [NAOI] |
A composite indicator which includes various neonatal adverse outcomes |
At delivery |
|
Secondary |
Frequency of infection |
Number of infections, including but not limited to: influenza, pneumonia, sepsis, acute respiratory infections, gastrointestinal |
Postpartum, through study completion, an average of 9 months |
|
Secondary |
Re-hospitalization rates |
Number of re-hospitalizations and emergency visits |
Postpartum, through study completion, an average of 9 months |
|
Secondary |
Composite indicator for complex chronic conditions |
Composite indicator includes: neurologic and neuromuscular; cardiovascular; respiratory; renal and urologic; gastrointestinal; hematologic or immunologic; metabolic; other congenital or genetic defect; and malignancy |
Postpartum, through study completion, an average of 9 months |
|
Secondary |
Infant death |
Infant death |
Postpartum, through study completion, an average of 9 months |
|